Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Denikitug · GS-1811, JTX-18011

Monoclonal antibody · Immune activation, directed at C-C-chemokine receptor 8 (CCR8) · developed by GILEAD SCIENCES

Phase 2 Most advanced trial

GILD Developer

1 Registered trials

What is Denikitug?

Denikitug is a humanized afucosylated IgG1 monoclonal antibody targeting CCR8 on tumor-infiltrating regulatory T cells. It depletes CCR8-positive cells via antibody-dependent cell-mediated cytotoxicity to reactivate antitumor immune responses. It is studied in HER2-negative gastric and esophageal adenocarcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: GS-1811, JTX-18011, JTX-1811
Drug type: Monoclonal antibody
Targets: C-C-chemokine receptor 8 (CCR8)
Mechanism: Immune activation, directed at C-C-chemokine receptor 8 (CCR8)
Pathways: ADCC, antitumor immune response
Therapy area: Oncology
Developer: GILEAD SCIENCES (GILD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 2C6JX7UEN2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07546812	Phase 2	HER2-negative	Recruiting	GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Esophageal AdenocarcinomaGastric AdenocarcinomaGastroesophageal JunctionHER2-negative

Other drugs acting on CCR8

Tagmokitug Phase 1 TAK-188 Phase 1/2

More from GILEAD SCIENCES

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Denikitug

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z